Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making

The objective of this study is to cover the ways of solving the problem of understanding the results of two key methods of pharmacoeconomic analysis – budget impact and cost-effectiveness. It is important to note that pharmacoeconomic assessment based on this evidence often has controversial charact...

Full description

Saved in:
Bibliographic Details
Published in:Value in health regional issues 2017-09, Vol.13, p.61-66
Main Authors: Yagudina, Roza Ismailovna, Kulikov, Andrey Urievich, Serpik, Vjacheslav Gennadievich, Ugrekhelidze, Dzhumber Tengizovich
Format: Article
Language:English
Subjects:
budget impact analysis
Budgets
Cost-Benefit Analysis
cost-effectiveness analysis
Decision Making
Delivery of Health Care
Economics, Pharmaceutical
health care decision making
health economics
Health Policy
health technology assessment
Humans
pharmacoeconomic model
Technology Assessment, Biomedical - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study is to cover the ways of solving the problem of understanding the results of two key methods of pharmacoeconomic analysis – budget impact and cost-effectiveness. It is important to note that pharmacoeconomic assessment based on this evidence often has controversial character. The results of one type of analysis can characterize assessed health technology favorably, and the results of other critically. Pharmacoeconomic evidence is often a crucial part of decision-making in healthcare, that’s why clear understanding of combination of this two types of analysis is highly in demand. Authors propose methodological solution of the stated problem. This model is a useful tool in making unified pharmacoeconomic report based on cost-effectiveness analysis and budget impact analysis results. Use of this model preserves the meaning and significance of each type of pharmacoeconomic analysis. Three-dimensional pharmacoeconomic model proposes full account of both types of pharmacoeconomic analyses during conclusion preparation, the formation of a single consistent pharmacoeconomic conclusion. Though further validation of a tool is needed, presented model can be interesting for the professional community. The proposed model of combining budget impact and cost-effectiveness analysis can be used by healthcare decision-makers for obtaining reliable and transparent pharmacoeconomic data.
ISSN:2212-1099
2212-1102
DOI:10.1016/j.vhri.2017.07.006